Day One Biopharmaceuticals (NASDAQ:DAWN) Rating Increased to Hold at Wall Street Zen

robot
Abstract generation in progress

Wall Street Zen upgraded Day One Biopharmaceuticals (NASDAQ:DAWN) to a “Hold” rating. The company has a consensus “Hold” rating with an average target price of $23.29 from analysts. Despite the stock opening at its 12-month high, it reported a quarterly EPS miss, negative net margin, and negative ROE, with analysts forecasting a negative EPS for the current year.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin